These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 36474613)

  • 1. Prevalence and Risk Factors of Venous Thromboembolism in Critically Ill Patients with Severe COVID-19 and the Association between the Dose of Anticoagulants and Outcomes.
    Al-Dorzi HM; Alqirnas MQ; Hegazy MM; Alghamdi AS; Alotaibi MT; Albogami MT; Alhafi MM; Alwadani S; Elsharkawi A; Arabi YM
    J Crit Care Med (Targu Mures); 2022 Oct; 8(4):249-258. PubMed ID: 36474613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between standard Vs. Escalated dose venous thromboembolism (VTE) prophylaxis in critically ill patients with COVID-19: A two centers, observational study.
    Aljuhani O; Al Sulaiman K; Hafiz A; Eljaaly K; Alharbi A; Algarni R; Al Homaid S; Kahtani K; Alsulaiman T; Vishwakarma R; Al Ghamdi G; Alalawi M; Korayem GB
    Saudi Pharm J; 2022 Apr; 30(4):398-406. PubMed ID: 35136364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
    Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
    Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
    Spyropoulos AC; Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Mignatti A; Gianos E; Cohen M; Sharifova G; Lund JM; Tafur A; Lewis PA; Cohoon KP; Rahman H; Sison CP; Lesser ML; Ochani K; Agrawal N; Hsia J; Anderson VE; Bonaca M; Halperin JL; Weitz JI;
    JAMA Intern Med; 2021 Dec; 181(12):1612-1620. PubMed ID: 34617959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
    Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N
    Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Standard Versus Intermediate Prophylaxis Dose for Venous Thromboembolism Prophylaxis in Patients Hospitalized With COVID-19 Infection.
    Chakabva MS; Polina S; Brauner M; McGuire M; Brown Z; Akthar T; Todt M; Polina A; Nova FF
    Hosp Pharm; 2024 Feb; 59(1):94-101. PubMed ID: 38223865
    [No Abstract]   [Full Text] [Related]  

  • 7. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.
    Artifoni M; Danic G; Gautier G; Gicquel P; Boutoille D; Raffi F; Néel A; Lecomte R
    J Thromb Thrombolysis; 2020 Jul; 50(1):211-216. PubMed ID: 32451823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation.
    Poletto F; Spiezia L; Simion C; Campello E; Dalla Valle F; Tormene D; Camporese G; Simioni P
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.
    ; Sadeghipour P; Talasaz AH; Rashidi F; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Jamalkhani S; Khalili H; Yadollahzadeh M; Riahi T; Rezaeifar P; Tahamtan O; Matin S; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Bakhshandeh H; Amin A; Rafiee F; Baghizadeh E; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Dobesh PP; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Bikdeli B
    JAMA; 2021 Apr; 325(16):1620-1630. PubMed ID: 33734299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard dosing of enoxaparin versus unfractionated heparin in critically ill patient with COVID-19: a multicenter propensity-score matched study.
    Al Sulaiman K; Aljuhani O; Korayem GB; Hafiz A; Alalawi M; Badreldin HA; Altebainawi AF; Vishwakarma R; Alissa A; Alghamdi A; Alenazi AA; Al Enazi H; Alanazi S; Alhammad A; Alghamdi J; AlFaifi M; Al Sehli FA; Aldossari MA; Alhubaishi AA; Al-Ali AY; Al-Dorzi HM
    Thromb J; 2022 Dec; 20(1):74. PubMed ID: 36482388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID-19: The Swiss COVID-HEP randomized clinical trial.
    Blondon M; Cereghetti S; Pugin J; Marti C; Darbellay Farhoumand P; Reny JL; Calmy A; Combescure C; Mazzolai L; Pantet O; Ltaief Z; Méan M; Manzocchi Besson S; Jeanneret S; Stricker H; Robert-Ebadi H; Fontana P; Righini M; Casini A
    Res Pract Thromb Haemost; 2022 May; 6(4):e12712. PubMed ID: 35599701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venous Thromboembolism Prophylaxis in Low Body Weight Critically Ill Patients.
    Knox H; Edwin SB; Giuliano C; Paxton RA
    J Intensive Care Med; 2024 May; 39(5):493-498. PubMed ID: 38111295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19.
    Hamilton DO; Main-Ian A; Tebbutt J; Thrasher M; Waite A; Welters I
    Thromb J; 2021 Nov; 19(1):87. PubMed ID: 34781984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patients.
    Obi AT; Tignanelli CJ; Jacobs BN; Arya S; Park PK; Wakefield TW; Henke PK; Napolitano LM
    J Vasc Surg Venous Lymphat Disord; 2019 May; 7(3):317-324. PubMed ID: 30477976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action.
    Pavoni V; Gianesello L; Pazzi M; Stera C; Meconi T; Frigieri FC
    Thromb Res; 2020 Dec; 196():313-317. PubMed ID: 32977129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
    Ko A; Harada MY; Barmparas G; Chung K; Mason R; Yim DA; Dhillon N; Margulies DR; Gewertz BL; Ley EJ
    JAMA Surg; 2016 Nov; 151(11):1006-1013. PubMed ID: 27383732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of High-Dose Unfractionated Heparin Versus High-Dose Enoxaparin for Venous Thromboembolism Prevention in Morbidly Obese Hospitalized Patients.
    Mason SW; Barber A; Jones E; Chen SL; Moll S; Northam K
    Am J Med; 2020 Jun; 133(6):e249-e259. PubMed ID: 31862336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies.
    Bikdeli B; Talasaz AH; Rashidi F; Sharif-Kashani B; Farrokhpour M; Bakhshandeh H; Sezavar H; Dabbagh A; Beigmohammadi MT; Payandemehr P; Yadollahzadeh M; Riahi T; Khalili H; Jamalkhani S; Rezaeifar P; Abedini A; Lookzadeh S; Shahmirzaei S; Tahamtan O; Matin S; Amin A; Parhizgar SE; Jimenez D; Gupta A; Madhavan MV; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Mohebbi B; Piazza G; Kirtane AJ; Lip GYH; Krumholz HM; Goldhaber SZ; Sadeghipour P
    Thromb Res; 2020 Dec; 196():382-394. PubMed ID: 32992075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma.
    Karcutskie CA; Dharmaraja A; Patel J; Eidelson SA; Padiadpu AB; Martin AG; Lama G; Lineen EB; Namias N; Schulman CI; Proctor KG
    JAMA Surg; 2018 Feb; 153(2):144-149. PubMed ID: 29071333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombosis and Bleeding After Implementation of an Intermediate-Dose Prophylactic Anticoagulation Protocol in ICU Patients With COVID-19: A Multicenter Screening Study.
    Al-Abani K; Kilhamn N; Maret E; Mårtensson J
    J Intensive Care Med; 2022 Apr; 37(4):480-490. PubMed ID: 34821162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.